Kronisk bihulebetændelse og type 2-sygdom

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Kronisk bihulebetændelse og type 2-sygdom. / Aanæs, Kasper; Alanin, Mikkel Christian; Arndal, Elisabeth; Backer, Vibeke; Kiær, Eva Kirkegaard; Rubek, Niclas; Sørensen, Henrik Bredahl; von Buchwald, Christian.

I: Ugeskrift for Laeger, Bind 184, Nr. 10, V05210446, 07.03.2022.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Aanæs, K, Alanin, MC, Arndal, E, Backer, V, Kiær, EK, Rubek, N, Sørensen, HB & von Buchwald, C 2022, 'Kronisk bihulebetændelse og type 2-sygdom', Ugeskrift for Laeger, bind 184, nr. 10, V05210446. <https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-03/v05210446_web.pdf>

APA

Aanæs, K., Alanin, M. C., Arndal, E., Backer, V., Kiær, E. K., Rubek, N., Sørensen, H. B., & von Buchwald, C. (2022). Kronisk bihulebetændelse og type 2-sygdom. Ugeskrift for Laeger, 184(10), [V05210446]. https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-03/v05210446_web.pdf

Vancouver

Aanæs K, Alanin MC, Arndal E, Backer V, Kiær EK, Rubek N o.a. Kronisk bihulebetændelse og type 2-sygdom. Ugeskrift for Laeger. 2022 mar. 7;184(10). V05210446.

Author

Aanæs, Kasper ; Alanin, Mikkel Christian ; Arndal, Elisabeth ; Backer, Vibeke ; Kiær, Eva Kirkegaard ; Rubek, Niclas ; Sørensen, Henrik Bredahl ; von Buchwald, Christian. / Kronisk bihulebetændelse og type 2-sygdom. I: Ugeskrift for Laeger. 2022 ; Bind 184, Nr. 10.

Bibtex

@article{12bb190b21144436bc43b9b766aa19b3,

title = "Kronisk bihulebet{\ae}ndelse og type 2-sygdom",

abstract = "Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.",

keywords = "Chronic Disease, Humans, Nasal Polyps/complications, Quality of Life, Rhinitis/complications, Sinusitis/complications",

author = "Kasper Aan{\ae}s and Alanin, {Mikkel Christian} and Elisabeth Arndal and Vibeke Backer and Ki{\ae}r, {Eva Kirkegaard} and Niclas Rubek and S{\o}rensen, {Henrik Bredahl} and {von Buchwald}, Christian",

year = "2022",

month = mar,

day = "7",

language = "Dansk",

volume = "184",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "10",

}

RIS

TY - JOUR

T1 - Kronisk bihulebetændelse og type 2-sygdom

AU - Aanæs, Kasper

AU - Alanin, Mikkel Christian

AU - Arndal, Elisabeth

AU - Backer, Vibeke

AU - Kiær, Eva Kirkegaard

AU - Rubek, Niclas

AU - Sørensen, Henrik Bredahl

AU - von Buchwald, Christian

PY - 2022/3/7

Y1 - 2022/3/7

N2 - Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.

AB - Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.

KW - Chronic Disease

KW - Humans

KW - Nasal Polyps/complications

KW - Quality of Life

KW - Rhinitis/complications

KW - Sinusitis/complications

M3 - Tidsskriftartikel

C2 - 35315753

VL - 184

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 10

M1 - V05210446

ER -

ID: 329209300